Cover Image

Second allo-SCT in patients with lymphoma relapse after a first allogeneic transplantation. A retrospective study of the EBMT Lymphoma Working Party

The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients ⩾18 years who had received an alloHSCT_2 for lymphoma rela...

Full description

Saved in:
Bibliographic Details
Main Authors: Horstmann, Kristin Theres (Author) , Boumendil, A. (Author) , Finke, J. (Author) , Finel, H. (Author) , Kanfer, E. (Author) , Milone, G. (Author) , Russell, N. (Author) , Bacigalupo, A. (Author) , Chalandon, Y. (Author) , Diez-Martin, J. L. (Author) , Ifrah, N. (Author) , Chacon, M. Jurado (Author) , Dreger, Peter (Author)
Format: Article (Journal)
Language:English
Published: 9 March 2015
In: Bone marrow transplantation
Year: 2015, Volume: 50, Issue: 6, Pages: 790-794
ISSN:1476-5365
DOI:10.1038/bmt.2015.12
Online Access:Verlag, lizenzpflichtig, Volltext: https://doi.org/10.1038/bmt.2015.12
Verlag, lizenzpflichtig, Volltext: https://www.nature.com/articles/bmt201512
Get full text
Author Notes:K. Horstmann, A. Boumendil, J. Finke, H. Finel, E. Kanfer, G. Milone, N. Russell, A. Bacigalupo, Y. Chalandon, J.L. Diez-Martin, N. Ifrah, M. Jurado Chacon, P. Dreger
Description
Summary:The aim of this registry-based retrospective study was to analyze the outcome of second allogeneic hematopoietic SCT (alloHSCT_2) performed in patients with lymphoma who had relapsed after a first allogeneic transplant (alloHSCT_1). Patients ⩾18 years who had received an alloHSCT_2 for lymphoma relapse between 2000 and 2011 were eligible. One hundred and forty patients were identified. The diagnosis was Hodgkin lymphoma (HL) in 31%, diffuse large B-cell lymphoma in 14%, T-cell lymphoma in 12%, indolent lymphoma in 19%, mantle cell lymphoma in 16% and other lymphomas in 8% of the patients. The median interval from alloHSCT_1 to alloHSCT_2 was 19 (range 4-116) months. Disease status at alloHSCT_2 was chemosensitive in 46%, refractory in 43% and unknown in 11% of the patients. Three-year PFS, OS, relapse incidence and nonrelapse mortality were 19%, 29%, 58% and 23%, respectively. PFS and OS were significantly affected by refractory disease at alloHSCT_2 and a short interval between alloHSCT_1 and alloHSCT_2. Long-term PFS was observed across all lymphoma subsets except for aggressive B-cell lymphoma. In conclusion, alloHSCT_2 is feasible and can result in long-term disease control in patients with lymphoma recurrence after alloHSCT_1, in particular if relapse occurs late and is chemosensitive.
Item Description:Gesehen am 14.09.2020
Physical Description:Online Resource
ISSN:1476-5365
DOI:10.1038/bmt.2015.12

Similar Items